[go: up one dir, main page]

WO1999045127A3 - Activation amelioree de promedicaments - Google Patents

Activation amelioree de promedicaments Download PDF

Info

Publication number
WO1999045127A3
WO1999045127A3 PCT/GB1999/000674 GB9900674W WO9945127A3 WO 1999045127 A3 WO1999045127 A3 WO 1999045127A3 GB 9900674 W GB9900674 W GB 9900674W WO 9945127 A3 WO9945127 A3 WO 9945127A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug activation
enhanced
prodrug
enhanced prodrug
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000674
Other languages
English (en)
Other versions
WO1999045127A2 (fr
Inventor
Ian James Stratford
Adam Vorn Patterson
Susan Mary Kingsman
On Kan
Leigh Griffiths
Kyriacos Mitrophanous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804841.6A external-priority patent/GB9804841D0/en
Priority claimed from GBGB9818103.5A external-priority patent/GB9818103D0/en
Priority claimed from GBGB9902081.0A external-priority patent/GB9902081D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to EP99937944A priority Critical patent/EP1068338A2/fr
Priority to CA002322664A priority patent/CA2322664A1/fr
Priority to AU32670/99A priority patent/AU763020B2/en
Publication of WO1999045127A2 publication Critical patent/WO1999045127A2/fr
Publication of WO1999045127A3 publication Critical patent/WO1999045127A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un agent d'activation de promédicaments renfermant: a) un domaine de localisation et b) un domaine d'activation de promédicaments destiné à activer un promédicament dans une cellule cible.
PCT/GB1999/000674 1998-03-06 1999-03-05 Activation amelioree de promedicaments Ceased WO1999045127A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99937944A EP1068338A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments
CA002322664A CA2322664A1 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments
AU32670/99A AU763020B2 (en) 1998-03-06 1999-03-05 Enhanced prodrug activation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9804841.6 1998-03-06
GBGB9804841.6A GB9804841D0 (en) 1998-03-06 1998-03-06 Enhanced pro-drug activation
GB9818103.5 1998-08-19
GBGB9818103.5A GB9818103D0 (en) 1998-08-19 1998-08-19 Enhanced pro-drug activation
GBGB9902081.0A GB9902081D0 (en) 1999-01-29 1999-01-29 Enhanced prodrug activation
GB9902081.0 1999-01-29

Publications (2)

Publication Number Publication Date
WO1999045127A2 WO1999045127A2 (fr) 1999-09-10
WO1999045127A3 true WO1999045127A3 (fr) 2000-02-24

Family

ID=27269233

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1999/000674 Ceased WO1999045127A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments
PCT/GB1999/000672 Ceased WO1999045126A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000672 Ceased WO1999045126A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments

Country Status (6)

Country Link
EP (1) EP1068338A2 (fr)
JP (1) JP2002505341A (fr)
CN (1) CN1357048A (fr)
AU (2) AU763020B2 (fr)
CA (1) CA2322664A1 (fr)
WO (2) WO1999045127A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142869A0 (en) * 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
EP1242456B1 (fr) * 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Anticorps
IL150510A0 (en) * 2000-01-07 2003-02-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
WO2001059152A2 (fr) * 2000-02-09 2001-08-16 Epidauros Biotechnologie Ag Polymorphismes dans le gene humain cyp2b6 et leur utilisation dans des applications diagnostiques et therapeutiques
CN1312283A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人细胞色素组成蛋白14和编码这种多肽的多核苷酸
PT1504108E (pt) 2002-02-01 2013-06-12 Oxford Biomedica Ltd Vetor lentiviral
CA2624707A1 (fr) * 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Methode de depletion selective de cellules hypoxiques
GB0608941D0 (en) * 2006-05-05 2006-06-14 Univ Montfort Methods
WO2009120396A2 (fr) * 2008-01-08 2009-10-01 The University Of California Compositions et procédés permettant de réguler l’expression de l’érythropoïétine, d’améliorer une anémie et de stimuler l’érythropoïèse
JP5488204B2 (ja) * 2010-05-31 2014-05-14 三菱電機株式会社 サイクロン分離装置及びこれを備えた電気掃除機
KR101650364B1 (ko) * 2012-12-05 2016-08-23 더백스 제네틱스 백신 코포레이션, 엘티디. 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
JP2017512068A (ja) * 2014-02-17 2017-05-18 ネステク ソシエテ アノニム マイトフュージンの方法及び使用
MX377487B (es) 2015-05-29 2025-03-04 Univ Mexico Nac Autonoma Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.
EP3214092A1 (fr) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one
US20190390221A1 (en) * 2016-11-02 2019-12-26 David Kiewlich Plasmid vectors for expression of large nucleic acid transgenes
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590530A2 (fr) * 1992-10-02 1994-04-06 BEHRINGWERKE Aktiengesellschaft Protéines de fusion pour l'activation de pro-médicaments
WO1996003515A2 (fr) * 1994-07-27 1996-02-08 Cancer Research Campaign Technology Limited Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997026918A2 (fr) * 1996-01-26 1997-07-31 Cancer Research Campaign Technology Limited Therapie par promedicament a enzyme dirige par ligand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590530A2 (fr) * 1992-10-02 1994-04-06 BEHRINGWERKE Aktiengesellschaft Protéines de fusion pour l'activation de pro-médicaments
WO1996003515A2 (fr) * 1994-07-27 1996-02-08 Cancer Research Campaign Technology Limited Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997026918A2 (fr) * 1996-01-26 1997-07-31 Cancer Research Campaign Technology Limited Therapie par promedicament a enzyme dirige par ligand

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKHLYNINA ET AL: "Nuclear Targeting of Chlorin e6 Enhances Its Photosensitizing Activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 33, 15 August 1997 (1997-08-15), pages 20328 - 20331, XP000198745, ISSN: 0021-9258 *
CHEN ET AL: "Potentiation of Cytochrome P450/Cyclophosphamide-based Cancer Gene Therapy by Coexpression of the P450 Reductase Gene", CANCER RESEARCH, vol. 57, 1 November 1997 (1997-11-01), pages 4830 - 4837, XP002113681 *

Also Published As

Publication number Publication date
AU3267099A (en) 1999-09-20
JP2002505341A (ja) 2002-02-19
WO1999045126A3 (fr) 2000-02-10
CA2322664A1 (fr) 1999-09-10
AU3266899A (en) 1999-09-20
AU763020B2 (en) 2003-07-10
EP1068338A2 (fr) 2001-01-17
WO1999045126A2 (fr) 1999-09-10
CN1357048A (zh) 2002-07-03
WO1999045127A2 (fr) 1999-09-10

Similar Documents

Publication Publication Date Title
WO1999045127A3 (fr) Activation amelioree de promedicaments
AU2001246441A1 (en) Antiadhesive carbohydrates
AU2002221550A1 (en) Multi-layered body, in particular a multi-layered film and method for increasing the forgery protection of multi-layered body
AU2002215116A1 (en) Expander
AU2001261150A1 (en) Methods and systems for compliance program assessment
AU2002239660A1 (en) Watermaking holograms
AU5150500A (en) Trocar for use in deploying an anastomisis device
AU2001292857A1 (en) Technique for operating a vehicle effectively and safely
AU2002227248A1 (en) Low work function material
MXPA03004758A (es) Pelicula y laminado biodegradable con capacidad de respirar.
AU2312399A (en) An improved aerosol valve
AU5419300A (en) Simplified storage barge
AU3678500A (en) Semi-optimal path finding in a wholly unknown environment
AU2000262575A1 (en) Method for localising direction and localisation arrangement
AU2002211717A1 (en) Stresscopins and their uses
AU2001262216A1 (en) Apoptotic agents
AU2002215741A1 (en) Semen storage
AU2001253104A1 (en) Methods for altering t cell and macrophage activation
AU6737800A (en) Polymer for chemically amplified resist and a resist composition using the same
AU6037699A (en) Techniques for trading commodities on a private trading system and not regulatedby the government
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2002241514A1 (en) Systems and methods for communicating in a business environment
AU2002223928A1 (en) Packaging arrangement for shirts and the like
AU2611899A (en) An electricity distribution board having a distribution terminal block, and a distribution terminal block for use in the electricity distribution board
WO2000078274A3 (fr) Composition de colorant capillaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 32670/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999937944

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2322664

Country of ref document: CA

Ref country code: CA

Ref document number: 2322664

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09656466

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999937944

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 32670/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999937944

Country of ref document: EP